



TETRAMATRIX PLATFORM EXPANSION - NEW PRECISION MEDICINE FRANCHISE, PARTNERSHIP AND REVENUE


HIGHLIGHTS:


- Tetratherix Limited (ASX:TTX) (**Tetratherix**) is pleased to announce a new precision medicine franchise leveraging our Tetramatrix™ platform polymer.
- This further endorses the versatility of the Tetramatrix™ platform polymer and complements the portfolio of bone regeneration, tissue spacing and tissue healing.
- Tetratherix confirms that all milestones outlined in the prospectus are on track, Tetratherix continues to expect 2 FDA approvals in the bone regeneration franchise in mid-CY26.
- The precision medicine franchise will be immediately revenue generating via an exclusive research & development (R&D) agreement (**Agreement**) with the US consumer health group Superpower Health Inc (**Superpower**).
- Under the Agreement, Superpower will pay TTX an exclusive licence payment of **US\$3 million per year for up to 10 years**.
- Additionally, Superpower will purchase Tetramatrix™ platform polymer (branded as STEPP) for nasal delivery of longevity and metabolic compounds such as GLP-1, peptides and hormones in the US market.
- In collaboration with major research institutions in Australia and the US, STEPP has been under stealth development by Tetratherix for over 5 years for the delivery of a range of active compounds.
- Due to the platform nature of our business, the precision medicine franchise is entirely additive and revenue generated under the Agreement is expected to strengthen Tetratherix's cash position without diverting resources from the core programs which are funded through to the start of FY28.

Ali Fathi, CTO of Tetratherix, said:

"Our precision medicine franchise is the culmination of more than 5 years of relentless, focused R&D in drug delivery - a journey driven by the conviction that science is only as powerful as its accessibility. I want to thank our research partners who have been instrumental in the development of this once in a generation, enabling technology which will lead to impact beyond our comprehension of what is possible in the way healthcare is delivered.

We are now poised to transform the lives of millions across the globe, initially within the high-impact landscapes of GLP-1s and peptide therapies with Superpower. Beyond the molecules themselves, this alliance will grant us early, scaled access to real world evidence allowing us to bridge the gap between clinical potential and actual patient outcomes in record time."





CONTEXT

What is STEPP and how does it work?

STEPP uses our Tetramatrix™ platform polymer in the exact same polymer formation as used in the bone regeneration and tissue healing franchises. STEPP is a carrier vehicle for nasal delivery of different compounds, once sprayed into the nostril it forms a sticky cushion on the lining inside the nose to anchor the compound in place. By sticking firmly to that surface the compounds stay locked in place rather than washing away, giving them time to move directly into the bloodstream. This sticky approach allows controlled release of the compounds and is a game-changer for complex treatments like GLP-1s and peptides.

Beyond just staying put on the nasal lining, STEPP acts as a protective bubble wrap for the compounds themselves. Delicate compounds like GLP-1s and peptides are easily broken down by the body's natural enzymes before they can even start working. STEPP wraps these fragile molecules in a defensive layer, shielding them from being destroyed. This ensures the compounds stay stable and active until they are absorbed. This means more of the compounds actually get to work; minimising waste, resulting in better patient results and importantly - **no needles**.

Is this opportunity in drug delivery new or have you been working on this for a while?

STEPP has been under stealth development by Tetratherix for over 5 years in collaboration with research institutions including the Terasaki Research Institute, Ab-Initio and the Woolcock Research Institute. This research has confirmed STEPP is technically superior to traditional drug carrier vehicles. Unlike traditional drug carrier systems, STEPP is physically unique and has the ability to interact with biologic agents in a way that other materials simply cannot. Since 2021 we have stress-tested STEPP against the most fragile and difficult-to-deliver biological payloads. We have tested STEPP for controlled delivery of mRNA, antibiotics, antibodies, proteins, peptides and growth factors. This body of work has cumulatively proven that we do not just have a passive scaffold; we have a proprietary smart carrier system that solves the stability issues plaguing modern biotechnology and simultaneously acts as a sticky and protective carrier in the nasal canal.

Will Knox, CEO of Tetratherix, said:

"The establishment of the precision medicine franchise will unlock and accelerate additional opportunities and the execution of the Superpower agreement significantly expedites revenues from product commercialisation which is a great result for the business and its shareholders. We are shifting the paradigm from complex implant technologies to active, high-velocity delivery systems - ensuring our technology isn't just a part of the future of medicine but the engine that drives it. This partnership is a masterstroke in speed and strategic alignment and we couldn't be more excited about working with Superpower as our first partner within our precision medicine franchise."



Is nasal delivery a new concept?

For decades the medical world has chased the holy grail of nasal delivery - trying to get complex drugs into the bloodstream through the nose instead of using needles or pills. The problem has always been a frustrating catch-22: on one hand most liquids just wash away or drip out within minutes, meaning the medicine does not have time to work or get into the bloodstream; to make matters worse, the nose is a naturally hostile environment with a specific pH balance and aggressive enzymes designed to break down foreign substances - this consequently degrades any cargo. Where scientists have tried to make the medicine sticky enough to stay put in the nasal canal, they usually have had to use harsh chemicals that irritated the delicate nasal lining. This triggered inflammation, which is the body's way of attacking a threat, effectively destroying the fragile cargo before it could ever be absorbed.

Our breakthrough is a deliberate fine balance of stickiness and a biostealth design. After over 5 years of R&D we have demonstrated the potential of STEPP to act as a gentle sticky cushion. It provides the grip needed to keep the compounds in place without screaming danger to the body and triggering inflammation. By staying neutral and non-inflammatory, our technology protects the compounds from the body's natural defences finally allowing delicate compounds like GLP-1s to cross the finish line safely and effectively and importantly - **no needles**.

Why nasal delivery is a big deal for drugs like GLP-1s and peptides etc?

We're leapfrogging the current battle of 'pen to pill'. The holy grail status of nasal delivery for GLP-1s and peptides boils down to two things: needles and nature. Currently, these life-changing drugs are almost exclusively delivered via subcutaneous injection (although attempts are being made at oral pill versions but they come with their own set of challenges). While effective, injections are a massive barrier for millions of people who have needle phobia or simply find daily or weekly shots a burden to manage. By moving this to a simple nasal spray, we turn a medical procedure into a five-second habit drastically improving the consistency of patients usage.

Beyond the convenience, the nose is a biological express lane to the bloodstream. Unlike a pill, which has to survive the acid bath of the stomach and then get filtered by the liver - a process that destroys fragile compounds like GLP-1s - the nasal lining is thin and rich with blood vessels. With STEPP the compounds are able to enter the body avoiding the digestive system entirely. STEPP finally solves the puzzle, providing a stable, sticky and non-inflammatory carrier allowing the delicate compounds to cross into the blood at scale.

Who is Superpower?

Superpower is a leader in the precision health movement, representing a shift toward what many call Pharma 2.0. Instead of the traditional, reactive model of medicine - where a patient only receives treatment after becoming ill - Superpower uses an AI-driven 'Test, Prescribe, Optimise' model. By integrating comprehensive biomarker tracking, such as blood panels and metabolic screening, they proactively identify health issues and generate personalised protocols that combine advanced medicine with specific lifestyle interventions. They are moving the industry away from one-size-fits-all prescriptions and toward a data-driven, consumer experience. By embedding our polymer technology into their ecosystem, we aren't just studying a new product; we aspire to become the delivery mechanism for a new era of preventative healthcare. This partnership allows us to gather on health outcomes and preferences in real-time.

How does the Superpower agreement work?

The Agreement is a strategic partnership that provides a consistent foundation for (subject to renewals by Superpower), up to 10 years of R&D. Superpower will pay to Tetratherix an annual US\$3 million IP license fee for exclusivity in the field in the United States of America. Additionally, Superpower may purchase our Tetramatrix™ platform polymer to combine it with high-demand active compounds to launch customised products - such as intranasal GLP-1 delivery. As such, beyond the annual licence fee, the model may generate high-margin revenue through the direct sale of the Tetramatrix™ platform polymer to Superpower. Real world evidence will be developed and shared under the Agreement on the performance of STEPP with different compounds in the use of needle-free but clinically reproducible drugs.

ASX RELEASE

16TH MARCH 2026



What is next for the precision medicine franchise?

The Agreement will be the initial focus area for the precision medicine franchise; collecting real world evidence in the fast evolving consumer health market in the US. As R&D progresses, Tetratherix may also consider polymer-enabled delivery of pharmaceutical agents, including but not limited to intravascular catheter delivery of therapeutics as well as intra-articular joint repair.

Are the existing franchises on track relative to commitments made at IPO?

Tetratherix confirms that all milestones across the bone regeneration, tissue spacing and tissue healing franchises remain on track. Tetratherix continues to expect 2 FDA approvals in the bone regeneration franchise in mid-CY26, which remains the primary near-term value catalyst for the business.

The precision medicine franchise is entirely additive. It leverages the same Tetramatrix™ platform polymer that underpins the existing franchises and has been developed in parallel without diverting resources from the core programs. The immediate revenue generation from the Agreement further strengthens Tetratherix's financial position with Tetratherix capitalised through to the start of FY28.

< ENDS >

Dr Ali Fathi and Will Knox will host an investor webinar on Tuesday 17 March at 9:00AM Sydney time to discuss the significance of the announcement. To register for the webinar click the following link:

https://us02web.zoom.us/webinar/register/WN_1OTgNZBRQ0S9Qo8mj2xB1g

Investors will be able to submit questions via the Q&A function within Zoom or alternatively via email to simon@nwrcommunications.com.au.

For any questions regarding this announcement, to receive regular Tetratherix announcements & updates and to engage with management join the [TTX Investor Hub](#) or for more information visit:

[TTX Investor Hub](#)

This announcement was authorised for ASX release by the board of Tetratherix.

For further information please contact:

Jacob Pfeffer

General Counsel | Company Secretary

+61 425 194 200

jacob.pfeffer@tetratherix.com

<https://tetratherix.com/>